Enovis (ENOV) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
30 Jun, 2026Opening remarks and agenda
The meeting was called to order by the chair, welcoming executive officers and directors, and noting the virtual format for expanded access and convenience.
Annual meeting procedures and proxy materials were made available to stockholders in advance.
The record date was March 30, 2026, and a quorum was confirmed.
Four items of business were on the agenda, as detailed in the proxy statement, with no additional proposals introduced.
Board and executive committee updates
All 10 nominated directors were present and subsequently elected by majority vote.
Overview of voting outcomes
All 10 director nominees were elected by majority vote.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026, was approved.
Advisory say on pay proposal received majority approval.
Amendment to the 2020 Omnibus Incentive Plan was approved by majority vote.
Final voting results to be posted online and filed on Form 8-K within four business days.
Latest events from Enovis
- Q2 2026 saw 5% organic growth, margin gains, strong cash flow, and reaffirmed guidance.ENOV
Q2 2026 - Double-digit growth, tech innovation, and ASC expansion drive strong outlook for 2026.ENOV
2026 CG Musculoskeletal Conference - Q1 2026 sales up 5%, margins and EPS improved, guidance reaffirmed amid macro headwinds.ENOV
Q1 2026 - Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.ENOV
Proxy filing - Board recommends all proposals, emphasizing governance, pay-for-performance, and ESG focus.ENOV
Proxy filing - 2025 saw robust sales growth, margin gains, and innovation, with 2026 guidance targeting further improvements.ENOV
Q4 2025 - Lima integration and new product launches drive growth, margin expansion, and innovation in 2025.ENOV
CG 2025 Musculoskeletal Conference - Q1 2025 sales up 8% with margin gains; revenue outlook raised, EBITDA trimmed on tariffs.ENOV
Q1 2025 - 6%-6.5% organic growth and margin expansion expected in 2025, driven by innovation and integration.ENOV
43rd Annual J.P. Morgan Healthcare Conference 2025